查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585696

出血性疾病治療市場：按疾病類型、藥物類別、分銷管道分類 - 全球預測 2025-2030

Bleeding Disorders Treatment Market by Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease), Drug Class (Antibrinolytics, Desmopressin, Fibrin Sealant), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年出血性疾病治療市場價值為135.6億美元，預計到2024年將達到148億美元，複合年成長率為9.29%，到2030年將達到252.5億美元。

出血性疾病治療市場包括廣泛的產品和服務，旨在管理因人體凝血機制缺陷或故障而導致異常或過度出血的疾病。由於血友病、血管性血友病和其他罕見出血性疾病等疾病的需要，該領域的應用涵蓋醫院、專科診所和居家醫療，最終用途包括有效且方便的治療選擇。根據市場洞察，意識的提高、重組基因技術的進步以及主動降低出血風險的預防性治療的快速採用正在推動市場的強勁成長。此外，政府支持和有利的報銷政策進一步支持市場擴張。基因療法和非替代療法的整合帶來了最近的商機，為製藥業的夥伴關係和創新提供了空間。然而，挑戰仍然存在，例如治療成本上升、監管要求更嚴格以及新興市場獲得治療的機會有限，這可能會阻礙市場擴張。在創新方面，半衰期延長的凝血因子、基因編輯技術和根據個人基因特徵客製化治療的個人化醫療方法等領域提供了潛在的成長途徑。公司可以透過專注於提高便利性和合規性的技術來受益，例如開發易於使用的交付系統和用於監控和管理的行動應用程式。出血性疾病治療市場的特點是發展迅速、競爭激烈，需要持續的研發投資。簡而言之，產業相關人員必須保持敏捷，加強研發力量，建立策略聯盟以抓住市場佔有率機會，同時利用需要解決的現有障礙。

主要市場統計
基準年[2023] 135.6億美元
預測年份 [2024] 148億美元
預測年份 [2030] 252.5億美元
複合年成長率（%） 9.29%

市場動態：揭示快速發展的出血性疾病治療市場的關鍵市場洞察

供需的動態交互作用正在改變出血性疾病治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 肝損傷和貧血的盛行率增加
    • 政府增加醫療保健支出
    • 顯著改善每個國家獲得醫療保健的機會
  • 市場限制因素
    • 缺乏熟練的專業人員和訓練有素的專業知識
  • 市場機會
    • 提高對出血性疾病的認知
    • 由於感染風險降低和研發投資增加，需求增加
  • 市場問題
    • 出血性疾病治療藥價高

波特五力：開拓出血性疾病治療市場的策略工具

波特的五力架構是了解出血性疾病治療市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解出血性疾病治療市場的外部影響

外部宏觀環境因素在塑造出血性疾病治療市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解出血性疾病治療市場的競爭格局

出血性疾病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣出血性疾病治療市場供應商的績效評估

FPNV 定位矩陣是評估出血性疾病治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製出血性疾病治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對出血性疾病治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肝病和貧血盛行率增加
      • 政府醫療費用支出增加
      • 經濟中獲得醫療保健的機會顯著改善
    • 抑制因素
      • 缺乏熟練的專業人員和訓練有素的專業知識
    • 機會
      • 提高對出血性疾病的認知
      • 由於感染風險降低以及研發方面的大量投資，需求增加
    • 任務
      • 治療出血性疾病的藥物成本很高
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章出血性疾病治療市場：依疾病類型

  • 介紹
  • A型血友病
  • B型血友病
  • 血管性血友病

第7章出血性疾病治療市場：依藥物類別

  • 介紹
  • 抗溶藥物
  • 去氨加壓素
  • 纖維蛋白膠
  • 血漿衍生凝血因子濃縮物
  • 重組凝血因子濃縮物

第8章出血性疾病治療市場：依分銷管道分類

  • 介紹
  • 配藥房
  • 醫院藥房
  • 零售藥房

第 9 章：美洲出血性疾病治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太出血性疾病治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲出血性疾病治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring
  • Emergent BioSolutions Inc.
  • Grifols International, SA
  • Kedrion SpA
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Xenetic Biosciences, Inc.
Product Code: MRR-437D45957F02

The Bleeding Disorders Treatment Market was valued at USD 13.56 billion in 2023, expected to reach USD 14.80 billion in 2024, and is projected to grow at a CAGR of 9.29%, to USD 25.25 billion by 2030.

The market for bleeding disorders treatment encompasses a wide range of products and services aimed at managing conditions characterized by abnormal or excessive bleeding due to deficiencies or dysfunctions in the body's clotting mechanism. Necessitated by conditions such as hemophilia, von Willebrand disease, and other rare bleeding disorders, the field's application spans across hospitals, specialty clinics, and home-care settings, with significant end-use coming from healthcare institutions and individuals seeking effective and convenient treatment options. The market insights reveal robust growth driven by increased awareness, advancements in recombinant technology, and a surge in prophylactic treatment adoption, which mitigates bleeding risks before they occur. Moreover, government support and favorable reimbursement policies further propel market expansion. Recent opportunities are presented by the integration of gene therapies and non-replacement therapies, offering room for partnerships and innovation within pharmaceutical circles. However, the market still faces challenges such as high treatment costs, stringent regulatory requirements, and limited access to treatment in developing regions, which could hinder expansion. In terms of innovation, areas such as extended half-life clotting factors, gene editing technologies, and personalized medicine approaches to tailor treatments to individual genetic profiles represent potential growth avenues. Businesses could benefit by focusing on technology that improves convenience and compliance, such as developing user-friendly delivery systems and mobile applications for monitoring and management. The bleeding disorders treatment market is characterized by rapid advancements and a competitive landscape, necessitating continuous research and development investments. In essence, industry stakeholders need to maintain agility, bolster their R&D wings, and develop strategic alliances to capture growth opportunities, while addressing prevailing barriers to maximize their market share efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 13.56 billion
Estimated Year [2024] USD 14.80 billion
Forecast Year [2030] USD 25.25 billion
CAGR (%) 9.29%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bleeding Disorders Treatment Market

The Bleeding Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the prevalence of liver disorders and anemia
    • Rising healthcare expenditure by the government
    • Considerable increase in healthcare accessibility in economies
  • Market Restraints
    • Lack of skilled professionals and trained expertise
  • Market Opportunities
    • Rising awareness regarding bleeding disorders
    • Rise in demand due to lower infection risks and high investments in research and development
  • Market Challenges
    • High cost of medications of bleeding disorders treatment

Porter's Five Forces: A Strategic Tool for Navigating the Bleeding Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bleeding Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bleeding Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bleeding Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bleeding Disorders Treatment Market

A detailed market share analysis in the Bleeding Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bleeding Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bleeding Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bleeding Disorders Treatment Market

A strategic analysis of the Bleeding Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Behring, Emergent BioSolutions Inc., Grifols International, S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hemophilia A, Hemophilia B, and Von Willebrand Disease.
  • Based on Drug Class, market is studied across Antibrinolytics, Desmopressin, Fibrin Sealant, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
  • Based on Distribution Channel, market is studied across Compounding Pharmacies, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of liver disorders and anemia
      • 5.1.1.2. Rising healthcare expenditure by the government
      • 5.1.1.3. Considerable increase in healthcare accessibility in economies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled professionals and trained expertise
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising awareness regarding bleeding disorders
      • 5.1.3.2. Rise in demand due to lower infection risks and high investments in research and development
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of medications of bleeding disorders treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bleeding Disorders Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hemophilia A
  • 6.3. Hemophilia B
  • 6.4. Von Willebrand Disease

7. Bleeding Disorders Treatment Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antibrinolytics
  • 7.3. Desmopressin
  • 7.4. Fibrin Sealant
  • 7.5. Plasma Derived Coagulation Factor Concentrates
  • 7.6. Recombinant Coagulation Factor Concentrates

8. Bleeding Disorders Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Compounding Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Bleeding Disorders Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bleeding Disorders Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorders Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals Inc.
  • 2. Amgen Inc.
  • 3. Baxter International Inc.
  • 4. Bayer AG
  • 5. Biogen Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. CSL Behring
  • 8. Emergent BioSolutions Inc.
  • 9. Grifols International, S.A.
  • 10. Kedrion S.p.A.
  • 11. Novo Nordisk A/S
  • 12. Octapharma AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Xenetic Biosciences, Inc.

LIST OF FIGURES

  • FIGURE 1. BLEEDING DISORDERS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BLEEDING DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLEEDING DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLEEDING DISORDERS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTIBRINOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COMPOUNDING PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023